Cancer Communications
indexed by SCI
BMC

Important notice

 

 

Cancer Communications is published by Wiley from 1 January 2020. The journal website is available at: https://onlinelibrary.wiley.com/journal/25233548

 

 

Cancer Communications 参与主办第十届广州国际肿瘤学会议,欢迎参会!

Cancer Communications 2021年影响因子突破15分

Cancer Communications 进入2021年中科院期刊分区表医学1区和肿瘤学1区

Cancer Communications 入选中国科协发布的高质量肿瘤学科技期刊T1分级目录

Cancer Communications (CJC) 获评“2019中国最具国际影响力学术期刊”


Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/30/2022   doi:10.1002/cac2.12394
C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis – evidence from clinical and pre-clinical data
Haiping Song, Hector Manuel Arredondo Carrera, Alexandria Sprules, Ying Ji, Tongsong Zhang, Jiepei He, Eleanor Lawrence, Alison Gartland, Jian Luo, Ning Wang
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/29/2022   doi:10.1002/cac2.12391
Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial
Qing Lin, Shangyou Zheng, Xianjun Yu, Meifu Chen, Yu Zhou, Quanbo Zhou, Chonghui Hu, Jing Gu, Zhongdong Xu, Lin Wang, Yimin Liu, Qingyu Liu, Min Wang, Guolin Li, He Cheng, Dongkai Zhou, Guodong Liu, Zhiqiang Fu, Yu Long, Yixiong Li, Weilin Wang, Renyi Qin
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/29/2022   doi:10.1002/cac2.12399
Activation mechanisms of clinically distinct B-Raf V600E and V600K mutants
Fuchen Liu, Xiaochen Feng, Jin Du, Minghao Ruan, Hui Liu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/26/2022   doi:10.1002/cac2.12395
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives
Zengli Fang, Qingcai Meng, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Yingjun Zhao, Xianjun Yu, Si Shi
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/24/2022   doi:10.1002/cac2.12392
Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection
Fuchen Liu, Xiaochen Feng, Jin Du, Minghao Ruan, Hui Liu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/24/2022   doi:10.1002/cac2.12398
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/22/2022   doi:10.1002/cac2.12397
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors
Fei Liu, Zixian Wang, Xiaofan Li, Zhen Zhang, Yue Yang, Junquan Chen, Dinghua Chen, Lingling Wu, Xiangyu Liu, Sujun Han, Fangming Wang, Wasilijiang Wahafu, Yibo Gao, Shancheng Ren, Nianzeng Xing, Guangyan Cai, Xiangmei Chen
[Abstract ]    [ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/17/2022   doi:10.1002/cac2.12396
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?
Ruimei Feng, Qingling Su, Xiaoyin Huang, Til Basnet, Xin Xu, Weimin Ye
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/17/2022   doi:10.1002/cac2.12393
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions
Yu-Fei Chen, Ying-ying Xu, Zhi-Ming Shao, Ke-Da Yu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 12/10/2022   doi:10.1002/cac2.12387

more papers...






Gastric cancer  

 

Edited by Yun Dai and Li Yan
 

This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.

 

Read thematic series > 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Tumor angiogenesis  

 

Edited by Francesco Pezzella
and Chao-Nan Qian 

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.

 

Read thematic series > 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Lung cancer 


 

Edited by Lin Yan and Wei Zhang  

 

Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.

 

Read thematic series > 



CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East,Guangzhou 510060, P.R.China